Skip to content
Catalyst brief · Phase 3 readout · 26 days

STELLAR-304: XL092 in Non-Clear Cell Renal Cell Carcinoma

Exelixis · $EXEL · built 19 Nov 2026 from 18 sourced facts · open on the radar

Analyst desk

Five AI analysts read the facts below. Each sentence shows the facts it rests on.

Trial design

  • The trial's main goal is to measure Duration of Progression-free survival, which will be assessed by a Blinded Independent Radiology Committee, adding credibility to the results F3
  • The trial is open label, which may introduce bias, but it is randomised, which helps to reduce bias and ensure that the groups are comparable F4 F5
  • The trial plans to enrol 317 patients, which is an increase from the initial target of 291, and it has two study arms, which will provide a comparison between the treatment groups F2 F7

Base rates

  • Historically, 47.7% of Phase 3 programmes in oncology moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F13
  • The company's record shows that 42% of its active Phase 2 and 3 trials have had their dates moved back by more than 6 months. F14
  • The DataCutoff timing model estimates this trial will finish close to its registry date, which is currently estimated to be around 15 Dec 2026. F12 F9
  • The trial's primary completion date is estimated to be in Q1 2027, according to the company's filing, which aligns with the registry date. F11 F9

Filings

  • The company has a cash position of $892M and is not burning cash, with positive operating cash flow over the last 12 months. F15 F16
  • There have been no open-market insider purchases or unplanned sales reported in the last 90 days. F17

The case for

  • Nothing the facts support.

The case against

  • The trial's open-label design may introduce bias, which could impact the credibility of the results, despite the randomisation and blinded assessment of the main goal. F3 F4 F5
  • The company's record shows that 42% of its active Phase 2 and 3 trials have had their dates moved back by more than 6 months, which raises concerns about the trial's ability to meet its estimated primary completion date. F14
  • Although the DataCutoff timing model estimates the trial will finish close to its registry date, there is still a risk of delay, especially given the company's history of pushing back trial dates. F12 F14

Open questions

  • Will the STELLAR-304 trial meet its primary endpoint of Duration of Progression-free survival?
  • Can the open-label design of the trial introduce significant bias in the results?

8 AI sentences were removed by the fact check.

The facts

The trial

  • F1STELLAR-304 is a Phase 3 trial of XL092 in Non-Clear Cell Renal Cell Carcinoma, sponsored by Exelixis (EXEL). source ↗
  • F2The trial plans to enrol 317 patients; the target first registered was 291. source ↗

What counts as success

  • F3Main goal as written in the registry: Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC). source ↗
  • F4Blinding: open label (no blinding). source ↗
  • F5Allocation: randomised. source ↗
  • F6The main goal is measured over: Approximately 27 months after the first subject is randomized. source ↗
  • F7Number of study arms: 2. source ↗

When

  • F9The registry gives the primary completion date as 15 Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
  • F10That date is 17.0 months later than the date first registered for this trial (Jul 2025). source ↗
  • F11In a filing of 29 Oct 2026 the company told investors to expect data in Q1 2027. This agrees with the registry date. source ↗
  • F12The DataCutoff timing model estimates this trial finishes close to its registry date. source ↗

Recruitment

Base rates

  • F13Historically 47.7% of Phase 3 programmes in oncology (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
  • F1442% of EXEL's active Phase 2 and 3 trials have moved their date back by more than 6 months. source ↗

Money, insiders and FDA

  • F15EXEL reported $892M in cash and short-term investments as of 2 Oct 2026 (10-Q). source ↗
  • F16EXEL's operating cash flow was positive over the last 12 months, so it is not burning cash. source ↗
  • F17No open-market insider purchases or unplanned sales were reported in the last 90 days. source ↗
  • F18EXEL has reported an FDA decision date of 3 Mar 2027 in an SEC filing. source ↗

How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.